Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States

Bullement, A. orcid.org/0000-0001-7091-0972, Knowles, E.S., DasMahapatra, P. et al. (2 more authors) (2021) Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States. PharmacoEconomics - Open, 5 (4). pp. 625-633. ISSN 2509-4262

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2021 The Author(s). This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Dates:
  • Accepted: 14 June 2021
  • Published (online): 15 July 2021
  • Published: December 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 30 Jul 2021 10:03
Last Modified: 09 Mar 2022 10:00
Status: Published
Publisher: Springer Nature
Refereed: Yes
Identification Number: https://doi.org/10.1007/s41669-021-00283-6
Related URLs:

Share / Export

Statistics